DDResponse is a Collaborative Project funded by the 7th Framework Programme of the European Commission in the theme Health. The start date of the project is 1 February 2011. It will end on 31 January 2015.
DDReponse - New hope for hereditary breast and ovarian cancer patientsIn 2011-2015, the EU-funded scientific project DDResponse tested and validated a new treatment for hereditary breast and ovarian cancer. This led to the Marketing Authorization of both the EU and the US for this new treatment, giving new hope to patients with relapsed hereditary ovarian cancer. Authorization for hereditary breast cancer is expected to follow soon.
Mark OConnor, senior scientist of AstraZeneca (UK), and Jan Hoeijmakers, professor in Genetics at Erasmus MC (NL) highlight the scientific basis for the new treatment and explain why this new treatment is so effective
|Mark OConnor||Jan Hoeijmakers|
The project DDresponse is now visualized in the animated movie
'DDresponse and Breast Cancer', available with
English and Dutch voice-over.
Brochure 'Hope on the Horizon'The DDResponse project aims to make significant progress towards personalized treatment and new drugs for breast cancer patients. In the brochure Hope on the Horizon you can read background information on breast cancer, its link with DNA repair and the long scientific journey towards better treatment. The brochure is available in English and Dutch.
DDResponse presents itself in two short movies:
Understanding the DNA Damage Response
and Meet the Scientists.
One of the most important developments in biomedical genetics over the last decade is the realisation that preservation of genetic integrity mediated by the DNA damage response (DDR) is both of enormous fundamental and medical importance. This holds most notably for cancer and many aging-related diseases, which have strong connections with DNA damage and genome maintenance.
As these diseases represent the main causes of mortality and morbidity in many countries world-wide, this 'DDResponse' proposal directly addresses the prevailing medical needs of all modern societies.
The principal objective of this collaborative project is to unlock the full potential of genome maintenance / DNA damage response (DDR) mechanisms to derive new therapies, assess individual susceptibility and predict individual responses to anti-cancer therapies that exploit DDR deficiencies, which appear universal in most, if not all, cancers. The proposal focuses on, but is not limited to, breast cancer.